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Statement of translational relevance 59 
Manipulation of the apoptosis pathway is an appealing strategy for cancer treatment using BH3 60 
mimetics such as ABT-263, although predictive biomarkers are required to identify patients who may 61 
benefit from their use. This study showed that ABT-263 exhibited broad in vivo efficacy against 62 
preclinical xenograft models of pediatric acute lymphoblastic leukemia (ALL). High MCL1 expression, 63 
at the mRNA and protein level, correlated with in vivo ABT-263 resistance, which was confirmed 64 
functionally by BH3 profiling. In addition, in vitro co-culture assays predicted in vivo ABT-263 65 
responses with high sensitivity and specificity. Therefore, a combination of functional assays could be 66 
used to predict ABT-263 activity in vivo. Given the strong efficacy of ABT-263 against a significant 67 
proportion of xenografts tested, these in-principle approaches could be included in the design of 68 
prospective clinical trials to determine if they can identify patients who may respond to treatment with 69 
this class of therapeutic agents.  70 
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ABSTRACT  71 
Purpose: Predictive biomarkers are required to identify patients who may benefit from the use of BH3 72 
mimetics such as ABT-263. This study investigated the efficacy of ABT-263 against a panel of patient-73 
derived pediatric acute lymphoblastic leukemia (ALL) xenografts and utilized cell and molecular 74 
approaches to identify biomarkers that predict in vivo ABT-263 sensitivity.  75 
Experimental Design: The in vivo efficacy of ABT-263 was tested against a panel of 31 patient-76 
derived ALL xenografts comprised of MLL-, BCP- and T-ALL subtypes. Basal gene expression 77 
profiles of ALL xenografts were analyzed and confirmed by quantitative RT-PCR, protein expression 78 
and BH3 profiling. An in vitro co-culture assay with immortalized human mesenchymal cells was 79 
utilized to build a predictive model of in vivo ABT-263 sensitivity.  80 
Results: ABT-263 demonstrated impressive activity against pediatric ALL xenografts, with 19 of 31 81 
achieving objective responses. Among BCL2 family members, in vivo ABT-263 sensitivity correlated 82 
best with low MCL1 mRNA expression levels. BH3 profiling revealed that resistance to ABT-263 83 
correlated with mitochondrial priming by NOXA peptide, suggesting a functional role for MCL1 84 
protein. Using an in vitro co-culture assay, a predictive model of in vivo ABT-263 sensitivity was built. 85 
Testing this model against 11 xenografts predicted in vivo ABT-263 responses with high sensitivity 86 
(50%) and specificity (100%).  87 
Conclusion: These results highlight the in vivo efficacy of ABT-263 against a broad range of pediatric 88 
ALL subtypes and shows that a combination of in vitro functional assays can be used to predict its in 89 
vivo efficacy.  90 
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INTRODUCTION 91 
Despite significant improvements in the treatment of childhood acute lymphoblastic leukemia (ALL) 92 
over the past 5 decades, curing those patients who relapse with this most common pediatric malignancy 93 
remains a significant challenge (1). These relapse cases are often associated with broad-range drug 94 
resistance (2), which remains a significant problem, thus highlighting the need to develop new 95 
therapies. Since evasion of apoptosis is recognized as one of the hallmarks of cancer (3), recent drug 96 
development has focused on targeting key components of the apoptosis signaling pathway (4). The 97 
BCL2 family of proteins includes key regulators of the intrinsic apoptosis pathway, with cell fate being 98 
determined by the balance of pro-survival (e.g. BCL2 and MCL1) and pro-apoptotic (e.g. PUMA, 99 
NOXA) members (5, 6).  100 
 BH3-mimetic drugs, such as ABT-737 and its orally available analog ABT-263, were specifically 101 
designed to inhibit pro-survival BCL2 family proteins (7). While these drugs bind with high affinity to 102 
BCL2, BCLW and BCLXL, they exhibit lower affinity for MCL1 and A1 (7, 8). ABT-737 and ABT-103 
263 have shown significant in vivo efficacy in preclinical xenograft models of hematolymphoid and 104 
solid malignancies (9, 10). While clinical trials of ABT-263 in adults have shown promising results 105 
(11-13), the main dose-limiting toxicity of thrombocytopenia has hindered its progression into pediatric 106 
patients. 107 
 Consistent with the low affinity of ABT-737 and ABT-263 for MCL1, several reports have shown 108 
an inverse correlation of MCL1 expression with sensitivity to these drugs (14-16). Other proteins in the 109 
BCL2 family have also been implicated in determining sensitivity or resistance. For example, high 110 
BCL2 expression was associated with increased ABT-737 sensitivity in Non-Hodgkin’s lymphoma 111 
(NHL) cell lines and in murine fetal liver cells (15). However, recent studies provided evidence that 112 
MCL1 or pro-survival protein expression levels contribute to, but are not sufficient determinants of, 113 
resistance (17-20). Disruption of the interaction between MCL1 and BAK increased drug sensitivity 114 
(17, 18) suggesting that protein-protein interactions, rather than absolute levels, play a critical role in 115 
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determining the sensitivity to BH3 mimetics. This interpretation was reinforced by “mitochondrial BH3 116 
profiling”, which utilizes a panel of peptides derived from BH3-domains and their binding to anti-117 
apoptotic proteins, to predict a cell’s susceptibility to apoptosis induction (19, 20). Mitochondrial 118 
sensitivity to the BAD BH3 peptide, which has a pattern of interaction with anti-apoptotic proteins 119 
similar to ABT-737 and ABT-263, was shown to predict in vitro ABT-737 sensitivity in small cell lung 120 
cancer, lymphoma, ALL and acute myelogenous leukemia cell lines (19). Clinical responses to 121 
conventional chemotherapy in acute leukemia, multiple myeloma and ovarian cancer instead were 122 
found to correlate with mitochondrial sensitivity with promiscuous interacting BH3 peptides such as 123 
Puma BH3 (20).  124 
 The Pediatric Preclinical Testing Program previously reported that ABT-263 was effective as a 125 
single agent against in vivo models of childhood cancer, and in particular pediatric ALL xenografts 126 
(10). The results suggested preferential efficacy against 2 T-cell ALL (T-ALL) in comparison to B-cell 127 
Precursor (BCP)-ALL xenografts, albeit testing against a small panel of xenografts. In the current study 128 
we tested the in vivo efficacy of ABT-263 against a diverse panel of 31 molecularly characterized 129 
xenografts derived from T-ALL, BCP-ALL and infant ALL with translocations of the Mixed Lineage 130 
Leukemia (MLL) gene (infant MLL-ALL), as well as the efficacy of ABT-263 in combination with 131 
established drugs. In order to identify determinants of in vivo ABT-263 response, we then correlated 132 
gene expression profiles, mitochondrial BH3 profiling and in vitro ABT-263 sensitivity with single-133 
agent ABT-263 efficacy. This powerful approach can be used as proof-of-principle to identify 134 
determinants of in vivo responses to other novel anti-leukemic drugs.   135 
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MATERIALS AND METHODS 136 
Xenografts and in vivo drug treatments 137 
All experimental studies were conducted with approval from the Animal Care and Ethics Committee of 138 
the University of New South Wales (Sydney, Australia). Procedures by which we established 139 
continuous xenografts from childhood ALL biopsies in immune-deficient NOD/SCID (NOD.CB17-140 
Prkdc
scid
/SzJ) or NOD/SCID, IL-2 receptor gamma negative (NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
/SzJ, NSG) 141 
mice, and tested their in vivo ABT-263 responses, have been described in detail previously (10, 21, 22). 142 
ALL subtypes were categorized at biopsy by their immunophenotype. Xenografts are available from 143 
the corresponding author upon request. ABT-263 (obtained from AbbVie under a standard Material 144 
Transfer Agreement) was administered orally at a dose of 100 mg/kg, daily for 21 days, as previously 145 
described (10). ABT-263 was also administered in combination with the conventional 146 
chemotherapeutic drugs vincristine (Baxter Healthcare, Toongabie, NSW, Australia; 1 mg/kg, Days 0 147 
and 7), dexamethasone (Sigma-Aldrich, Castle Hill, NSW, Australia, 15 mg/kg, Mon-Fri x 2 weeks) or 148 
L-asparaginase (Aventis, Lane Cove, NSW, Australia; 1,500 U/kg, Mon-Fri x 2 weeks) on a Mon-Fri x 149 
2 week schedule at least 1 hour following administration of the established drug. It was necessary to 150 
attenuate the dose of ABT-263 to 25 mg/kg when combined with vincristine, and to 50 mg/kg when 151 
combined with dexamethasone and L-asparaginase in order to achieve a tolerable dose. 152 
 Leukemia engraftment and progression were assessed in groups of 6-10 female mice each of 20-25 153 
g by weekly enumeration of the proportion of human CD45
+
 cells in the peripheral blood 154 
(%huCD45
+
)(22). Individual mouse event-free survival (EFS) was calculated as the days from 155 
treatment initiation until the %huCD45
+
 reached 25%. EFS was represented graphically by Kaplan-156 
Meier analysis. The efficacy of drug treatment was evaluated by leukemia growth delay (LGD), 157 
calculated as the difference between the median EFS of vehicle control and drug-treated cohorts, as 158 
well as an Objective Response Measure (ORM), modeled after stringent clinical criteria as described 159 
previously (21). Detailed methodology is presented in the Supplementary Methods and Supplementary 160 
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Table S1. Responses were also expressed in a “COMPARE-like” format, which combines EFS and 161 
ORMs around the midpoint (0) representative of SD. Bars to the right or left of the midpoint represent 162 
Objective Responses or non-Objective Responses, respectively. Significant and non-significant 163 
differences in EFS distribution between control and treated cohorts are represented by solid or dotted 164 
bars, respectively. Xenografts were excluded from analysis if >25% of mice within a cohort 165 
experienced non-leukemia-related toxicity or morbidity. Mice were excluded from the study if they 166 
developed spontaneous murine lymphomas. 167 
 To evaluate interactions between drugs in vivo, Therapeutic Enhancement was considered if the 168 
EFS of mice treated with the drug combination was significantly greater than those induced by both 169 
single agents used at their maximum tolerated doses (23, 24).  170 
 171 
Protein expression 172 
Preparation of extracts from xenograft cells previously harvested from the spleens of engrafted mice, 173 
determination of protein concentrations, and analysis of cellular proteins by immunoblotting have been 174 
described in detail elsewhere (25). Membranes were probed with anti-MCL1 (Genesearch, Danvers, 175 
MA) and anti-actin antibodies (Sigma-Aldrich) followed by horseradish peroxidase–conjugated 176 
secondary antibody (GE Healthcare, Buckingham, UK). Signal was detected by Immobilon Western 177 
Chemiluminescent HRP Substrate (Merck Millipore, Billerica, MA) and visualized using a VersaDoc 178 
5000 Imaging System (Bio-Rad, Hercules, CA). Data were analyzed with QuantityOne software 179 
(Version 4.00; Bio-Rad). 180 
 181 
RNA extraction, real-time quantitative reverse transcription PCR (RT-qPCR) and gene 182 
expression analysis 183 
Total RNA was extracted from xenograft cells, previously harvested from the spleens of engrafted mice 184 
and cryopreserved, using a combination of Trizol (Invitrogen, Carlsbad, CA) and Qiagen 185 
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(Germantown, MD) RNeasy kit. RNA was purified with QIAGEN RNeasy spin columns according to 186 
the manufacturer’s protocol. RNA purity was considered acceptable if the ratio of OD260/280 was 187 
between 1.8 and 2.0. For use in microarrays, the RNA integrity number was determined using an 188 
Agilent Bioanalyzer (Walbronn, Germany) and considered acceptable if >7. 189 
  RT-qPCR was carried out using standard techniques. First-strand cDNA was synthesized using 2 190 
μg of total RNA, random primers (Roche, Mannheim, Baden-Württemberg, Germany), and M-MLV 191 
Reverse Transcriptase (Invitrogen). Primers and probes for MCL1 were purchased from Life 192 
Technologies (Carlsbad, CA) (Hs03043899_m1). Quantitative real-time PCR analysis was carried out 193 
in triplicate under the following cycling conditions: 50°C for 2 min and 95°C for 10 min, followed by 194 
40 cycles of 95°C for 15 s and 60°C for 1 min. Elongation factor-1α (EF1α) was used as an internal 195 
normalization standard in each reaction (primers EF-1αF, 5′-CTGAACCATCCAGGCCAAAT-3′; EF-196 
1αR, 5′-GCCGTGTGGCAATCCAAT-3′; Probe, 5′-VIC-AGCGCCGGCTATGCCCCTG-TAMRA-197 
3′).   198 
 RNA samples were used to prepare cRNA with Illumina TotalPrep RNA Amplification Kit (Life 199 
Technologies). cRNA was then hybridized to Illumina Human Beadchip HT12 Arrays. Gene 200 
expression data sets were analyzed using GenePattern v3.2.3 as we have previously described (26). 201 
Gene expression data sets can be accessed at www.ncbi.nlm.nih.gov/geo (accession no. GSE52991; 202 
reviewer’s access: 203 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=glwjgwusrnadfsr&acc=GSE52991). Benjamini 204 
and Hochberg’s False Discovery Rate (FDR) (27) measurement and Smyth’s unadjusted p-value (28) 205 
were used for evaluation of differential gene expression. Gene expression heatmaps were generated 206 
using GenePattern, whereby the range of color coding extends from minimum to maximum values per 207 
gene (per row). In each case red indicates high, and blue low, level of expression. Unsupervised 208 
hierarchical clustering was performed using the Hierarchical Clustering module in GenePattern using 209 
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the entire 47,323 probes representative of 34,694 genes present in the Illumina Human Beadchip HT-12 210 
Arrays.  211 
 212 
Assessment of mitochondrial priming by BH3 profiling 213 
Xenograft cells permeabilized by digitonin were exposed to BH3 peptides derived from BAD, NOXA 214 
and PUMA proteins, and mitochondrial depolarization measured using the fluorescent dye JC-1, as we 215 
have previously described(20). Comparison of mitochondrial depolarization of Non-Responders versus 216 
Responders was performed using a t-test (unpaired, 2-tailed).  217 
 218 
In vitro cytotoxicity assays 219 
The in vitro sensitivity of xenograft cells to ABT-263 was assessed by co-culture using hTERT-220 
immortalized primary bone marrow mesenchymal stromal cells (hTERT-MSCs), as described 221 
previously (29) and detailed in the Supplementary Methods. Briefly, hTERT-MSCs were seeded at 222 
2,000 cells/well in a 384-well plate (Greiner) in serum-free medium (AIM-V®, Life Technologies). 223 
After 24 h, 20,000 viable leukemia cells and ABT-263 were added to final concentrations of 1, 2.5, 5, 224 
10, 25, 50, 100 and 1000 nM in duplicate. After 72 h of incubation live cell numbers were determined 225 
using 7-AAD analyses by flow cytometry (BD FACSCanto
TM
II). Data were normalized using 226 
SPHERO
TM
 AccuCount Particles (Spherotech, IL). Examples of flow cytometry analysis are included 227 
in Supplementary Figure S1. To build a predictive model of in vivo ABT-263 sensitivity we used upper 228 
and lower limits of the 95% confidence intervals of the proportion of live cells following exposure to 229 
10 nM ABT-263 in vitro.  230 
 231 
Statistical analysis 232 
EFS curves were compared by logrank test. Differences in responses to single-agent ABT-263 in vivo 233 
between MLL-ALL, BCP-ALL and T-ALL xenografts were evaluated using one-way ANOVA and 234 
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Tukey’s multiple comparison analysis as well as Chi square test. Pearson’s correlation test was utilized 235 
for all datasets with normal distribution, which included gene expression analysis versus LGD, and 236 
MCL1 Illumina mRNA versus MCL1 RT-qPCR mRNA levels. Spearman’s correlation test was used to 237 
compare MCL1 RT-qPCR mRNA versus protein expression. Comparison of MCL1 RT-qPCR mRNA 238 
and protein levels between Non-Responders and Responders was performed using a Mann-Whitney 239 
test. Significance was inferred from tests with P-values lower than 0.05.  240 
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RESULTS 241 
Gene expression profiles of ALL xenografts reflect the primary disease   242 
In order to identify cell and molecular determinants of in vivo ABT-263 responses in pediatric ALL, 243 
panels of a total of 31 xenografts were established from direct patient explants representative of MLL- 244 
ALL (8 infant MLL-ALLs, and one pediatric MLL-ALL, ALL-3), BCP-ALL (n=7) and T-ALL (n=15) 245 
and were characterized by gene expression profiling. The patient demographics focused on high-risk or 246 
poor outcome cases: infant MLL-ALL is a known high-risk ALL subtype; the T-ALL panel included 247 
three xenografts derived from Early T-cell Precursor (ETP) ALL patients (ETP-1, ETP-2 and ETP-3), a 248 
very high-risk subgroup (30); the BCP-ALL and non-ETP T-ALL panels included 4/7 and 9/12 249 
patients, respectively, who had relapsed and/or died from their disease (22, 30, 31). More detailed 250 
descriptions of the infant MLL-ALL and expanded T-ALL xenograft panels will be reported elsewhere. 251 
Chromosomal translocations in the original biopsy sample, where known, are summarized in 252 
Supplementary Table S2. 253 
 Unsupervised hierarchical clustering of xenograft basal gene expression profiles revealed three 254 
distinct branches reflecting each leukemia subtype (Figure 1A). The MLL-ALL and BCP-ALL panels 255 
appeared more closely related and distinct from the T-ALL xenografts. Xenograft ALL-3 was 256 
originally classified by immunophenotype as a BCP-ALL but clustered with the MLL-ALLs. Upon 257 
further investigation it was confirmed that ALL-3 harbors an MLL gene rearrangement (Supplementary 258 
Table S2). The 4 MLL-ALLs with translocations involving chromosome 19 (MLL-6, -8, -14 and ALL-259 
3) clustered separately from 2 MLL-ALLs with chromosome 4 translocations (MLL-2 and -7) (Figure 260 
1A and Supplementary Table S2). The three ETP-ALLs, while not clustering as a separate branch, did 261 
cluster within the T-ALL panel (Figure 1A). 262 
 We next identified subtype-specific differentially expressed genes using the LimmaGP (Cowley et 263 
al, manuscript in preparation) module in GenePattern, whereby each subtype was compared to the 264 
remaining two ALL subtypes (1-vs-rest comparison). Subtype specific genes were determined with a 265 
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cut-off value of FDR<0.05 At this level of stringency there were 2,141 MLL-ALL specific genes, 643 266 
BCP-ALL specific genes and 18,692 T-ALL specific genes (Supplementary Table S3). The top 25 267 
differentially expressed probesets between each xenograft panel included previously identified subtype-268 
specific genes, such as MEIS1, ZNF827 and CCNA1 in MLL-ALL (32), MME (CD10) in BCP-ALL, 269 
and components of the CD3 receptor (CD3D, CD3E, CD3G and CD247), CD2 and SH2D1A in T-ALL 270 
(33) (Figure 1B). ALL subtype specific genesets were identified using GSEApreranked module in 271 
GenePattern with FDR<0.05 (Supplementary Table S4). For MLL-ALL, the top 4 genesets reflected 272 
MLL-specific genesets, for BCP-ALL, 9 B-cell specific genesets were identified within the top 30 273 
genesets and for T-ALL, 6 T-cell specific genesets were identified within the top 10 genesets. 274 
Therefore, these analyses confirmed the xenograft subtype classification according to the primary 275 
disease. 276 
 277 
ABT-263 exhibits single-agent in vivo efficacy against a broad range of pediatric ALL subtypes 278 
We previously reported the results of in vivo ABT-263 testing against a panel of 6 ALL xenografts, 279 
with higher sensitivity observed in 2 T-ALL compared with 4 BCP-ALL xenografts (10). In order to 280 
further investigate this possible subtype-specific in vivo efficacy of ABT-263 against pediatric ALL we 281 
expanded the analysis to the 31 xenografts described above. ABT-263 significantly delayed the 282 
progression of 29/31 xenografts tested (Table 1, Figure 2A-C and Supplementary Figures S2–S4). 283 
LGDs ranged from 0.5 (ALL-2; P=0.46) to 78 (ALL-31; P=0.0008) days. When stratified according to 284 
ALL subtype the median LGDs were 17.9 days for MLL (range 3.1–53.7), 25.8 days for BCP-ALL 285 
(range 0.5->37.9) and 29.6 days for T-ALL (range 4.0-78) (Figure 2D and Table 1). There was no 286 
significant differential efficacy of ABT-263 against any of the three ALL subtypes. 287 
 ABT-263 elicited objective responses in 19/31 xenografts, with 3 MCRs, 11 CRs and 5 PRs (Table 288 
1 and Figure 2). Figure 2E represents the in vivo ABT-263 responses of each xenograft panel in a 289 
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“COMPARE-like” format. In agreement with the LGD data, no significant differences were observed 290 
between the ALL subtypes. 291 
 We previously showed that the in vivo sensitivity of a subset of these xenografts to an induction-292 
type regiment of vincristine, dexamethasone and L-asparaginase (VXL) correlated with the clinical 293 
outcome of the patients from whom the xenografts were derived (34). However, the in vivo ABT-263 294 
sensitivity of the same subset of xenografts did not correlate with their VXL responses (R=0.46, 295 
P=0.18; Supplementary Figure S5), indicating that ABT-263 can exert significant in vivo efficacy 296 
against ALL xenografts that are resistant to established drugs.   297 
 A complete summary of results is provided in Supplementary Figures S2–S4 and Supplementary 298 
Table S5, including total numbers of mice, number of mice that died (or were otherwise excluded), 299 
numbers of mice with events and average times to events, LGD values, as well as numbers in each of 300 
the ORM categories and “treated over controls” (T/C) values. 301 
 302 
MCL1 gene expression correlates with in vivo ABT-263 sensitivity in ALL xenografts 303 
We next analyzed basal BCL2 family gene expression levels in relation to in vivo ABT-263 sensitivity 304 
across the 31 xenografts using 2 approaches. Both approaches were applied to the entire xenograft 305 
cohort as well as all three subtypes separately. The first approach assessed the correlation between gene 306 
expression and progression delay (LGD) (Pearson product moment correlation coefficient), with a 307 
positive correlation denoting genes whose higher expression was associated with ABT-263 sensitivity, 308 
and vice versa. Using this approach, MCL1 expression correlated significantly with in vivo ABT-263 309 
sensitivity across the entire xenograft panel (R=-0.43, P=0.015, Figure 3A), indicating that high MCL1 310 
expression was associated with in vivo resistance. BCLXL/XS (R=0.79, P=0.01) and BCLW (R=0.69, 311 
P=0.039) showed significant positive correlations between expression and drug sensitivity in the MLL-312 
ALL panel (Supplementary Figure S6, Supplementary Table S6). In contrast, no significant 313 
correlations were observed in the BCP-ALL panel (Supplementary Figure S7, Supplementary Table 314 
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S6) while BID levels were negatively correlated with sensitivity in the T-ALL xenografts (R=-0.52, 315 
P=0.046) (Supplementary Figure S8, Supplementary Table S6). 316 
 In the second approach xenografts were stratified according to their ORM into Responders (PRs, 317 
CRs and MCRs) and Non-Responders (PDs and SDs) and differentially expressed genes were 318 
identified using an unadjusted P-value of ≤0.05 from an empirical Bayes moderated t-test (28). MCL1 319 
was the BCL2 family member with the strongest differential expression among the entire xenograft 320 
panel between Responders and Non-Responders (Figure 3B and Supplementary Table S6). This was 321 
also the case for the MLL-ALL (P=0.027) and BCP-ALL (P=0.008) subtypes (Supplementary Figures 322 
S6 and S7, Supplementary Table S6). Among the MLL-ALL xenografts, differential expression of BIM 323 
(P=0.044); also reached statistical significance, being paradoxically lower in the Responders compared 324 
to Non-Responders (Supplementary Figure S6 and Supplementary Table S6). Similarly, HRK 325 
(P=0.005) was significantly increased in the BCP-ALL Responders (Supplementary Figure S7 and 326 
Supplementary Table S6), while BAK (P=0.03) and NOXA (P=0.049) were significantly increased in 327 
the T-ALL Non-Responders and Responders, respectively (Supplementary Figure S8 and 328 
Supplementary Table S6). 329 
 Both of the above analysis approaches had also been applied to the entire 34,694 genes represented 330 
on the Illumina Beadchip HT-12 Arrays, although no genes satisfied the significance or FDR cutoff 331 
criteria (data not shown). 332 
 Since MCL1 expression was the strongest overall predictor of in vivo ABT-263 response across the 333 
entire panel of 31 xenografts, we next assessed MCL1 expression at the mRNA and protein levels. 334 
While RT-qPCR analysis showed a significantly higher MCL1 expression in the Non-Responders 335 
(Figure 3C), this difference was not confirmed by increased MCL1 protein levels (Figure 3D, 336 
Supplementary Figure S9). Despite no significant difference in MCL1 protein levels between Non-337 
Responders and Responders, MCL1 mRNA levels correlated between qRT-PCR and microarray 338 
(Figure 3E), and MCL1 protein levels significantly correlated with MCL1 mRNA expression measured 339 
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by qRT-PCR (Figure 3F). MCL1 protein expression was also investigated after exposure of 2 Non-340 
Responders and 2 Responders to ABT-263 in vitro, however no consistent differences were observed 341 
(data not shown). Due to these discrepancies in MCL1 protein expression, we next assessed BCL2 342 
family protein function with respect to in vivo ABT-263 sensitivity using BH3 profiling of the entire 343 
xenograft panel 344 
 345 
BH3 profiling identifies MCL1 function as a determinant of in vivo ABT-263 sensitivity 346 
The mitochondrial priming assay measures mitochondrial sensitivity to peptides derived from the BH3 347 
domains of pro-apoptotic BCL2 family proteins. The in vivo ABT-263 responses of the xenografts 348 
were then compared with the status of mitochondrial priming by the ability of BH3 peptides derived 349 
from PUMA, BAD and NOXA to cause mitochondrial depolarization in xenograft cells. PUMA BH3 350 
interacts promiscuously with all 5 anti-apoptotic proteins, BAD BH3 interacts with BCL2, BCLXL and 351 
BCLW (like ABT-263), while NOXA BH3 interacts only with MCL1. Out of the three peptides only 352 
NOXA-induced mitochondrial depolarization significantly discriminated between Non-Responder and 353 
Responder groups (Figure 3G-I), implicating MCL1 protein function as a major determinant of in vivo 354 
ABT-263 response. The extent of mitochondrial depolarization did not correlate with leukemia 355 
progression (LGD) for any of the peptides tested (data not shown). 356 
 357 
In vitro ABT-263 sensitivity of ALL xenografts predicts their in vivo responses  358 
We next tested whether the in vitro ABT-263 responses of ALL xenografts predicted their in vivo 359 
sensitivity. Using a co-culture method (29) a predictive model was built using a training subset of 17 360 
xenografts (Figure 4A). Exposure of xenograft cells to a range of ABT-263 concentrations (1 µM–1 361 
nM) revealed that 10 nM gave the best discrimination between in vivo Non-Responders and 362 
Responders (Figure 4B and Supplementary Figure S10). Using the 95% confidence intervals of both 363 
Responder and Non-Responder groups, a three-tier classification was created. It was established that 364 
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>14.9% live cells after drug treatment (lower limit of confidence interval of Non-Responders) stratified 365 
xenografts as Non-Responders, <8.0% (upper limit of confidence interval of Responders) as 366 
Responders, and those in between were considered as unclassified. Three xenografts (MLL-1, MLL-7 367 
and ETP-3) were excluded from the analysis since their survival was not supported by the co-culture 368 
assay. 369 
 The in vivo ABT-263 responses of the remaining 11 xenografts, constituting the test set, were 370 
initially blinded. When the test set was classified using the predictive model 7 xenografts were 371 
correctly classified according to their in vivo ABT-263 responses (Figure 4C), 2 were incorrectly 372 
classified and 2 were unclassified., The sensitivity and specificity of the predictive method 373 
(Supplementary Figure S11) were 50% and 100%, respectively (leaving out of this assessment the two 374 
unclassified xenografts). 375 
 Live and dead cell analysis at 72 h for each xenograft is shown in Supplementary Figure S12, 376 
which includes the % live/dead cells, the absolute numbers of live/dead cells, and the number of live 377 
cells seeded and harvested. In addition, a comparison of the co-culture system versus single cell 378 
suspension was performed with 5 xenograft samples, and revealed the importance of the co-culture 379 
assay to assess ALL xenograft cell sensitivity to ABT-263 in vitro (Supplementary Figure S13). 380 
 381 
In vivo efficacy of ABT-263 in combination with established chemotherapeutic drugs 382 
We next sought to test the efficacy of ABT-263 in paired combinations with established drugs against 383 
xenografts representative of the two most common pediatric ALL subtypes, BCP-ALL and T-ALL. 384 
Three xenografts were selected based on their range of single-agent ABT-263 responses (ALL-2, 385 
resistant; ALL-19, intermediate; ALL-31, sensitive) (Table 1). Preliminary tolerability experiments 386 
showed that it was necessary to attenuate the dose of ABT-263 to 25 mg/kg when combined with 387 
vincristine, and to 50 mg/kg when combined with dexamethasone and L-asparaginase. Out of the three 388 
xenografts tested, the combination of ABT-263 with vincristine caused Therapeutic Enhancement only 389 
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in ALL-31 and although for ALL-19 it induced an LGD of >73.7 days, due to variation among 390 
individual mice it did not reach statistical significance versus ABT-263 alone (Supplementary Tables 391 
S7 and S8 and Supplementary Figure S14). The dexamethasone/ABT-263 combination did not exert 392 
Therapeutic Enhancement for any xenografts, while ABT-263 in combination with L-asparaginase 393 
exerted Therapeutic Enhancement in ALL-31, and the P value approached significance for ALL-19. 394 
Thus, the expectation that ABT-263 would broadly enhance the in vivo efficacy of established 395 
chemotherapeutic drugs was not met.  396 
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DISCUSSION 397 
We report the utilization of a large panel of ALL xenografts to define the cell and molecular 398 
determinants of in vivo ABT-263 responses using gene expression profiling, BH3 profiling, and in vitro 399 
co-culture cytotoxicity assays. The principal findings of this study are: (1) ABT-263 is effective in vivo 400 
as a single agent against pediatric ALL xenografts; (2) MCL1 gene expression and MCL1 protein 401 
function correlate with in vivo ABT-263 sensitivity; and (3) an in vitro co-culture cytotoxicity assay is 402 
able to predict in vivo ABT-263 responses of ALL xenografts with a high level of sensitivity and 403 
specificity. 404 
 Xenograft models of pediatric ALL are recognized to accurately recapitulate several cellular and 405 
molecular features of the original disease, including blast morphology, immunophenotype, clonal 406 
selection, gene expression profiles and genetic lesions (22, 31, 35-37). Our results describe the subtype 407 
classification of a large panel of xenografts, which were appropriately clustered into MLL-ALL, BCP- 408 
and T-ALL subtypes by gene expression profiling. Differentially expressed genes and GSEA analysis 409 
within each subtype were consistent with the primary disease state, and a BCP-ALL xenograft 410 
previously established from a teenage female (31) was re-classified as an MLL-ALL based in this 411 
analysis. Sub-clusters within each xenograft subtype were also consistent with specific chromosomal 412 
translocations. For example, all 4 of the MLL-ALL xenografts harboring a translocation involving 413 
chromosome 19 co-clustered in 1 sub-branch of MLL-ALL, while the 3 ETP-ALLs appeared under 1 414 
sub-branch of T-ALL. 415 
 Despite our previous report of ABT-263 efficacy testing against 6 ALL xenografts indicating a 416 
preferential effect against 2 T-ALL xenografts (10), in this study ABT-263 exhibited a broad spectrum 417 
of in vivo efficacy with no apparent subtype specificity, and induced regressions in 19 of 31 xenografts. 418 
However, all 3 xenografts that achieved MCRs were T-ALL, suggesting that ABT-263 may be 419 
particularly useful for the treatment of aggressive T-ALL cases. ABT-263 also induced regressions (2 420 
PRs and 1 CR) in the 3 ETP-ALL xenografts. ETP-ALL arises from a subset of thymocytes that are 421 
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recent emigrants from the bone marrow to the thymus, retaining stem-cell-like features and 422 
multilineage differential potential, and is a particularly aggressive and refractory T-ALL subtype (30).  423 
 In this study we also attempted to identify cell and molecular signatures that could be used to 424 
predict in vivo responsiveness to single-agent ABT-263. Studies primarily carried out using cultured 425 
cell lines have consistently identified elevated MCL1 expression to be associated with resistance to 426 
ABT-737 and ABT-263 (14-16, 38). While our study is no exception, we believe this to be the first 427 
report to strongly implicate MCL1 in resistance to ABT-263 in vivo using a large panel of direct-patient 428 
explants established as continuous xenografts. This relationship only became apparent when we 429 
restricted the gene expression analysis to the BCL2 gene family, a finding that we attribute to the 430 
heterogeneity in gene expression profiles between and within each xenograft subtype. Nevertheless, the 431 
molecular determinants of in vivo ABT-263 sensitivity in pediatric ALL are complex since additional, 432 
and occasionally paradoxically, BCL2 family genes were significantly associated with ABT-263 433 
responses within individual xenograft subtypes. 434 
 A confounding factor in our analysis was that, while MCL1 mRNA expression determined by RT-435 
qPCR correlated with MCL1 protein expression and microarray data, MCL1 protein expression did not 436 
reach statistical significance between the ABT-263 Responders and Non-Responders despite a higher 437 
trend in the Non-Responders (Figure 3D). Technical issues associated with the harvesting, purifying 438 
and cryopreservation of spleen-derived cells and the very short half-life of MCL1 (< 1 h) (39, 40) may 439 
have contributed to this lack of correlation due to MCL1 protein degradation (Supplementary Figure 440 
S15). Moreover, Gao and Koide reported that there are 2 MCL1 splice variants regulated by SF3B1, 441 
one with pro- and another with anti-apoptotic functions (41). However, we found no correlation 442 
between SF3B1 levels and drug sensitivity (data not shown). Similarly, Boiani et al. showed that the 443 
HSP70 protein BAG3 stabilizes MCL1, thereby extending its half-life (42). Similarly, we found no 444 
correlation between BAG3 expression and in vivo ABT-263 efficacy (data not shown). Due to the 445 
aforementioned complexity associated with correlating gene expression profiles and MCL1 protein 446 
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expression with in vivo ABT-263 sensitivity, we next tested the established functional readouts of 447 
mitochondrial priming status by BH3 profiling and in vitro chemosensitivity testing. Mitochondrial 448 
depolarization induced by NOXA peptide correlated with in vivo ABT-263 sensitivity (Figure 3I), 449 
thereby strongly implicating MCL1 function. However, this finding differs from a previous report that 450 
identified a correlation between BIM, but not NOXA, peptide-induced mitochondrial depolarization 451 
and clinical complete response to conventional therapy using pediatric ALL biopsy samples (20). 452 
 Murine or human bone marrow-derived stromal cells improve the ex vivo survival of pediatric 453 
ALL cells (29, 43) while both co-culture and tetrazolium dye-based assays have been used for 454 
chemosensitivity testing in this disease (44-46). In our study ABT-263 sensitivity of pediatric ALL 455 
xenograft cells co-cultured with MSC-hTERT cells provided a sensitive (50%) and highly specific 456 
(100%) prediction of in vivo response. This model accurately predicted resistance, since all 5 of the in 457 
vivo Non-Responders were correctly identified. However, while both of the xenografts predicted to be 458 
Responders were correct, the model incorrectly predicted no response in 2 of the in vivo Responders. 459 
Therefore, this model could be further refined, since while it might accurately predict which patients 460 
are unlikely to respond, it can potentially fail to identify a subset of patients who may benefit from such 461 
treatment. Nevertheless, we believe this to be the first report of a functional assay that is able to 462 
accurately predict in vivo single-agent ABT-263 responses.  463 
 Despite substantial evidence, primarily using cultured cell lines, that ABT-737 and ABT-263 can 464 
potentiate the effects of standard chemotherapeutic drugs both in vitro and in vivo (9, 16, 47, 48), using 465 
stringent criteria we only observed Therapeutic Enhancement in 2 instances in which ABT-263 was 466 
combined with 3 established drugs against 3 xenografts. While our results are not sufficient to make 467 
broad conclusions for combining ABT-263 with these established drugs for patient management, we 468 
reason that this divergence from previous reports is due to the necessity to attenuate the ABT-263 dose 469 
in all of the combinations (down to 25 mg/kg in the case of vincristine), while maintaining the maximal 470 
ABT-263 dose (100 mg/kg) in the single-agent arms. Future investigations in which small molecule 471 
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BCL2 inhibitors with reduced thrombocytopenic effects, such as ABT-199 (49, 50), are combined with 472 
established drugs in pediatric ALL may prove more beneficial. 473 
 In summary, BCL2-targeted agents appear as a promising class of anti-cancer drugs for the 474 
treatment of pediatric ALL, with no apparent specificity across MLL-ALL, BCP-ALL or T-ALL 475 
subtypes. MCL1 expression and function appear to be important determinants of in vivo ABT-263 476 
sensitivity, while an in vitro co-culture assay predicted in vivo ABT-263 responses with high sensitivity 477 
and specificity. This combined cell and molecular analysis provides a proof-of-concept approach for 478 
prioritizing other novel drugs for pediatric ALL clinical trials, and for the identification of biomarkers 479 
predictive of in vivo response.  480 
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FIGURE LEGENDS 644 
Figure 1. Comparison of MLL-ALL, BCP-ALL and T-ALL xenografts by gene expression 645 
profiling. A total of 31 ALL xenografts (MLL-ALL, n=9; BCP-ALL, n=7; T-ALL, n=15) were 646 
profiled on Illumina Human HT-12 Beadchip arrays. (A) Non-supervised hierarchical clustering of all 647 
xenografts. (B) Heatmap of the top 25 up-regulated genes that were specific to MLL-ALL, BCP-ALL 648 
and T-ALL subtypes, ordered according to their P-value. The colours in the heatmaps represent the 649 
relative expression per gene across all samples. Red indicates relative high expression and blue 650 
indicates relative low expression.  651 
 652 
Figure 2. In vivo single-agent ABT-263 responses of pediatric ALL xenografts. Responses of 653 
representative xenografts from the (A) MLL-ALL, (B) BCP-ALL and (C) T-ALL sub-panels treated 654 
with ABT-263 (100 mg/kg for 21 days, black lines) or vehicle control (gray lines). In each case the left 655 
panels represent the %huCD45
+
 of individual mice over time, while the right panels the proportion of 656 
mice remaining event-free. Shaded areas indicate the treatment period. (D) Comparison of the 657 
Leukemia Growth Delay (LGD) of ALL xenograft subtypes in response to ABT-263 treatment. Each 658 
data point represents a single xenograft; the horizontal bar represents the median. (E) “COMPARE-659 
like” plot of the midpoint difference representing the median ORM of xenografts shown in Table 1. 660 
 661 
Figure 3. Cell and molecular determinants of the in vivo sensitivity of pediatric ALL xenografts 662 
to ABT-263. (A) Xenografts (columns) were ordered by increasing Leukemia Growth Delay (LGD) 663 
from left to right, with each row representing a BCL2 family member. (B) Xenografts were stratified 664 
into Non-Responders (NR) and Responders (R) then ordered by increasing LGD from left to right 665 
within each category. The colours in the heatmaps represent the relative expression per gene across all 666 
samples. Red indicates relative high expression and blue indicates relative low expression. (C) 667 
Comparison of MCL1 mRNA expression between Non-Responders and Responders by RT-qPCR. (D) 668 
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 28 
Comparison of MCL1 protein expression between Non-Responders and Responders by immunoblot. 669 
(E) Correlation between MCL1 mRNA expression by microarray and RT-qPCR. (F) Correlation 670 
between MCL1 protein expression by immunoblot and MCL1 mRNA expression by RT-qPCR. In C-F 671 
each data point represents a single xenograft. (G-I) The percentage of mitochondrial depolarization 672 
induced by BH3 peptides derived from (G) PUMA, (H) BAD and (I) NOXA peptides in xenograft cells 673 
was plotted for individual xenografts stratified as Non-Responders or Responders according to Table 1.  674 
 675 
Figure 4. In vitro sensitivity of pediatric ALL xenograft cells to ABT-263 predicts their in vivo 676 
responses. (A) Xenografts were sub-grouped into a Training Set to build a predictive model, and a Test 677 
Set to test the model. (B) Percentages of live leukemia cells after exposure to ABT263 (10 nM, 72 h). 678 
Each data point represents an individual xenograft. Lines indicate the geometric mean with 95% 679 
confidence interval indicated by the bars. (C) Actual and predicted in vivo ABT-263 responses of the 680 
test xenografts. 681 
 682 
 683 
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Table 1. In vivo responses of pediatric ALL xenografts to ABT-263.  
  EFS (days)     
ALL 
lineage 
Xenograft 
ID 
Vehicle 
Control 
ABT-263 LGD 
(days) 
P value 
(logrank
) 
Median 
ORM 
ORM 
Heatmap 
MLL-
ALL 
MLL-1 19.2 39.7 20.5 0.0003 6 PR 
MLL-2 14.8 26.8 12.0 0.002 6 PR 
MLL-3 8.3 34.1 25.8 0.0002 8 CR 
MLL-5 8.7 14.6 5.9 0.0006 2 PD2 
MLL-6 6.3 29.1 22.8 0.0002 2 PD2 
MLL-7 12.7 30.6 17.9 0.0002 6 PR 
MLL-8 13.7 16.8 3.1 0.0002 0 PD1 
MLL-14 8.7 24.9 16.2 0.0006 2 PD2 
ALL-3 9.6 63.3 53.7 0.008 8 CR 
BCP-
ALL 
ALL-2# 4.7 5.2 0.5 0.46 0 PD1 
ALL-4# 1.5 28.6 27.1 0.029 2 PD2 
ALL-7 6.8 31.4 24.6 0.0003 8 CR 
ALL-10 7.5 33.3 25.8 0.008 8 CR 
ALL-11 20.2 56.3 36.1 0.008 8 CR 
ALL-17# 2.5 24.2 21.7 0.0001 2 PD2 
ALL-19# 5.0 >43 >37.9 0.002 8 CR 
 
 
 
 
 
ALL8# 11.8 62.8 51.0 0.004 10 MCR 
ALL-16# 18.2 85.5 67.3 0.0002 10 MCR 
ALL-27 3.3 19.6 16.3 0.30 2 PD2 
ALL-29 4.4 48.8 44.0 0.0002 8 CR 
ALL-30 5.3 16.2 10.9 0.004 2 PD2 
T-ALL 
 
 
 
 
ALL-31 13.9 91.9 78.0 0.0008 10 MCR 
ALL-32* 6.7 18.9 12.2 0.0002 2 PD2 
ALL-33* 6.0 37.8 31.8 0.0003 8 CR 
ALL-42 1.9 5.9 4.0 0.0002 2 PD2 
ALL-43 14.0 43.9 29.9 0.0002 8 CR 
 
 
 
ETP-
ALL 
ALL-44 11.4 27.2 15.8 0.0005 2 PD2 
ALL-47 11.9 41.5 29.6 <0.0001 8 CR 
ETP-1 7.8 23.8 16.0 0.0002 6 PR 
ETP-2 14.2 44.7 30.5 0.0002 8 CR 
ETP-3 20.0 32.5 12.5 0.0002 6 PR 
* dose of ABT-263 reduced to 75mg/kg on day 9 (ALL-32) or day 13 (ALL-33) due to toxicity 
#
 in vivo ABT-263 sensitivity data previously reported(10). 
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